Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.
Perspective Therapeutics Inc (CATX) is a clinical-stage radiopharmaceutical company advancing targeted alpha therapies for cancer treatment. This page provides investors and medical professionals with essential updates on the company’s pioneering work in theranostics, which combines therapeutic isotopes with precision imaging diagnostics.
Access real-time announcements including clinical trial milestones, regulatory developments, and strategic partnerships. Our curated news collection offers transparent insights into the company’s progress with 212Pb-based therapies and their applications across oncology specialties.
Key updates cover FDA submissions, peer-reviewed research findings, and manufacturing advancements. Bookmark this page to monitor how CATX’s proprietary targeting peptides and isotope delivery systems are reshaping radiation oncology.
PharmaLogic Holdings Corp., a contract development organization, has signed a Master Services Agreement with Viewpoint Molecular Targeting, Inc. (NYSE AMERICAN: CATX) for the development of theranostics VMT-01 and VMT-α-NET. These radiopharmaceuticals are aimed at diagnosing and treating metastatic melanoma and neuroendocrine tumors. PharmaLogic will supply doses for Perspective's clinical trials, leveraging its expertise in radiopharmaceuticals. This collaboration is expected to enhance the precision of cancer treatments, with clinical trials set to begin enrollment soon, and preliminary results anticipated later this year.
FAQ
What is the current stock price of Perspective Therapeutics (CATX)?
What is the market cap of Perspective Therapeutics (CATX)?
